Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | MMP1 | P03956 | 3/20 | 0.34 |
| ▸ | MMP3 | P08254 | 3/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15998895 | 0.87 | HPGDS (0.41) | NAMPTKDM4ENAAAF2PLG | |
| SCHEMBL5639144 | 0.86 | NAMPT (0.47) | NAMPTNAAAMMEACEMMP1 | |
| SCHEMBL12875984 | 0.82 | NAMPT (0.45) | NAMPTMMEACEMMP1MMP3 | |
| SCHEMBL2464736 | 0.81 | NAMPT (0.43) | NAMPTKDM4ENAAAMMEACE | |
| SCHEMBL2460778 | 0.79 | GAA (0.46) | NAMPTNAAAF2 | |
| SCHEMBL2456099 | 0.79 | GAA (0.46) | NAMPTNAAAF2 | |
| SCHEMBL2456097 | 0.79 | GAA (0.46) | NAMPTNAAAF2 | |
| SCHEMBL5637239 | 0.79 | GAA (0.46) | NAMPTNAAAF2 | |
| SCHEMBL14684463 | 0.78 | NAMPT (0.40) | NAMPTNAAA | |
| SCHEMBL12840777 | 0.78 | NAMPT (0.40) | NAMPTNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | NAMPT 1311/4885KDM4E 921/4885NAAA 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.